Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease

Annalena Venneri, William J. McGeown, Michael F. Shanks

Research output: Contribution to journalArticlepeer-review

Abstract

Brain grey matter density changes were quantified using voxel based morphometry in 26 patients with minimal to mild Alzheimer's disease (AD) treated with three cholinesterase inhibitors over 20 weeks. Patients whose drug treatment also inhibited butyrylcholinesterase did not show the widespread cortical atrophic changes in parietotemporal regions invariably reported in untreated AD patients, and which were detectable in the subgroups treated with selective acetxlcholinesterase inhibition. This finding is the first empirical evidence that dual cholinesterase inhibition may have neuroprotective potential in AD.

Original languageEnglish
Pages (from-to)107-110
Number of pages4
JournalNeuroReport
Volume16
Issue number2
DOIs
Publication statusPublished - Feb 8 2005

Keywords

  • Alzheimer's disease
  • Cholinesterase inhibitors
  • Dementia
  • Disease progression
  • Donepezil
  • Galantamine
  • Grey matter
  • MRI
  • Neuroimaging
  • Rivastigmine
  • Treatment

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease'. Together they form a unique fingerprint.

Cite this